Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

89
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
89
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

73
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
73
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

43
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
43
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

53
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
53
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

50
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
50
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

330
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
330

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rethinking residual sex effects in frailty-adjusted ICU mortality.

European journal of internal medicine·2026
Same author

Impact of cancer on mortality in critically ill patients with sepsis: a propensity score-matched analysis.

Scientific reports·2026
Same author

Fluorescence Method-Based Nonlinear Hybridization Chain Reaction for Highly Sensitive and Specific Detection of HER2.

International journal of analytical chemistry·2026
Same author

Overview of methodology and characteristics of national acute coronary syndrome registries in high-income countries: a scoping review.

European heart journal open·2026
Same author

Preliminary evaluation of DeepSeek-R1 and GPT-5.3 in selected PET/CT clinical scenarios: patient preparation, report interpretation, and diagnostic reasoning.

Frontiers in medicine·2026
Same author

Long Short-Term Memory Modeling of the Chinese Traditional Mongolian Osteopathy Rolling Method Using Adam and the Hodrick-Prescott Filter.

Journal of visualized experiments : JoVE·2026

Related Experiment Video

Updated: Sep 26, 2025

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
06:48

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome

Published on: March 23, 2022

2.5K

Barth Syndrome Cardiomyopathy: An Update.

Jing Pang1,2, Yutong Bao1,2, Kalia Mitchell-Silbaugh1

  • 1Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA.

Genes
|April 23, 2022
PubMed
Summary

Barth syndrome (BTHS) is an X-linked mitochondrial disorder affecting cardiolipin (CL) biosynthesis due to TAZ gene mutations. This review covers BTHS cardiomyopathy

Keywords:
Barth syndromeTAFAZZINcardiolipincardiomyopathy

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.8K
Sarcomere Shortening of Pluripotent Stem Cell-Derived Cardiomyocytes using Fluorescent-Tagged Sarcomere Proteins.
08:37

Sarcomere Shortening of Pluripotent Stem Cell-Derived Cardiomyocytes using Fluorescent-Tagged Sarcomere Proteins.

Published on: March 3, 2021

4.6K

Related Experiment Videos

Last Updated: Sep 26, 2025

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome
06:48

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome

Published on: March 23, 2022

2.5K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.8K
Sarcomere Shortening of Pluripotent Stem Cell-Derived Cardiomyocytes using Fluorescent-Tagged Sarcomere Proteins.
08:37

Sarcomere Shortening of Pluripotent Stem Cell-Derived Cardiomyocytes using Fluorescent-Tagged Sarcomere Proteins.

Published on: March 3, 2021

4.6K

Area of Science:

  • Biochemistry
  • Genetics
  • Cardiology

Background:

  • Barth syndrome (BTHS) is an X-linked mitochondrial lipid disorder.
  • It is caused by mutations in the TAFAZZIN (TAZ) gene, impacting cardiolipin (CL) biosynthesis.
  • Cardiomyopathy is a primary clinical manifestation of BTHS.

Purpose of the Study:

  • To review key findings on BTHS cardiomyopathy.
  • To summarize clinical features, molecular mechanisms, and therapeutic targets.
  • To highlight recent advancements and experimental models.

Main Methods:

  • Literature review of studies on BTHS cardiomyopathy.
  • Analysis of clinical data and molecular mechanisms.
  • Evaluation of recent Taz knockout mouse models.

Main Results:

  • Significant progress in understanding BTHS cardiomyopathy's clinical features and molecular basis.
  • Identification of therapeutic targets for BTHS.
  • Development of Taz knockout mouse models for research.

Conclusions:

  • Recent studies have advanced the understanding of BTHS cardiomyopathy.
  • Taz knockout mouse models are valuable for studying the disease and testing therapies.
  • Further research is crucial for developing effective treatments for BTHS cardiomyopathy.